

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant:**      **Murphy, et al.**

**Serial No.:**      **Not Yet Known**

**Group:** **Not Yet Assigned**

**Filing Date:**    **Filed Herewith**

**Examiner:** **Not Yet Assigned**

**Title:**            **METHODS OF MODIFYING EUKARYOTIC CELLS**

**July 21, 2003**

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents  
US Patent & Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

☒ (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

or

☐ (c) After (b) above, but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or any action that otherwise closes prosecution in the application. Accordingly, the undersigned certifies as follows:

☐ (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart

foreign application not more than three months prior to the date of the filing of this IDS; or

- [ ] (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

or

- [ ] This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p);

or

- [ ] (d) After (c) above, but on or before payment of the issue fee and the undersigned certifies as follows:

- [ ] (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

- [ ] (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

and

- [ ] This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p).

#### **REQUEST FOR TRANSFER OF REFERENCE COPIES**


- [ ] Applicants respectfully request that the cited references filed in the Information Disclosure Statement submitted in connection with parent application USSN 09/784,859, U.S. file date 16 February 2001, be transferred to the subject application for consideration by the Examiner. In addition, applicants enclose a copy of WO 94/02602 published February 3, 1994.

Att. Docket No.: REG 780BZ  
USSN: Not Yet Known  
File Date: Filed Herewith  
Murphy, et al.  
Information Disclosure Statement

### **Fees**

The fee required for the filing of this Information Disclosure Statement is estimated to be \$\_\_\_\_\_. Applicants hereby authorize such charge to Deposit Account number 18-0650. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-050.

Respectfully submitted



Linda O. Palladino

Reg. No. 45,636

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. REG 780BZ

Serial No. Not Yet Known

Date Filed Filed Herewith

Applicant: Murphy and Yancopoulos

For METHODS OF MODIFYING EUKARYOTIC CELLS

July 21, 2003

## U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	<u>5,789,215</u>	<u>8/4/98</u>	<u>Berns, et al.</u>	_____	_____
_____	<u>5,770,429</u>	<u>6/23/98</u>	<u>Lonberg, et al.</u>	_____	_____
_____	<u>5,436,149</u>	<u>7/25/95</u>	<u>Barnes</u>	_____	_____

## FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation Yes No</u>
_____	WO94/02602	02/03/1994	PCT		

## OTHER DOCUMENTS

Examiner  
Initials

\_\_\_\_\_ NATURE, Vol. 317, 1985, Smithies, O., et al., "Insertion of DNA sequences into the human chromosomal  $\beta$ -globin locus by homologous recombination," pp. 230-234.

- \_\_\_\_\_ CELL, Vol. 51, 1987, Thomas, K.R., and Capecchi, M.R., "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells," pp. 503-512.
- \_\_\_\_\_ NATURE, Vol. 369, 1994, Cheng, S., et al., "Long PCR," pp. 684-685.
- \_\_\_\_\_ PCR METHODS AND APPLICATIONS, 1994, Foord, O.S., and Rose, E.A., "Long-distance PCR," pp. 3:S149-S161.
- \_\_\_\_\_ NUCLEIC ACIDS RESEARCH, Vol. 20, 1992, Ponce, M.R., and Micol, J.L., "PCR amplification of long DNA fragments," p.623.
- \_\_\_\_\_ GENE TARGETING-A PRACTICAL APPROACH, 2<sup>nd</sup> Ed., 2000, Edited by Joyner, A.L., Hasty, P. et al., Chapter 1 "Gene targeting, principles, and practice in mammalian cells," pp. 1-35.
- \_\_\_\_\_ MOLECULAR AND CELLULAR BIOLOGY, Vol. 12, 1992, Deng, C., and Capecchi, M.R., "Reexamination of Gene Targeting Frequency as a Function of the Extent of Homology between the Targeting Vector and the Target Locus," pp. 3365-3371.
- \_\_\_\_\_ NATURE GENETICS, Vol. 20, 1998, Zhang, Y., et al., "A new logic for DNA engineering using recombination in *Escherichia coli*," pp. 123-128.
- \_\_\_\_\_ NUCLEIC ACIDS RESEARCH, Vol. 27, 1999, Angrand, P., et al, "Simplified generation of targeting constructs using ET recombination," pp. 16(e).

- \_\_\_\_ NUCLEIC ACIDS RESEARCH, Vol. 27, 1999, Muylers, J.P., et al., "Rapid modification of bacterial artificial chromosomes by ET-recombination," pp. 1555-1557.
- \_\_\_\_ Genomics, Vol. 64, 1999, Hill, F., et al., "BAC Trimming: Minimizing Clone Overlaps," pp. 111-113.
- \_\_\_\_ NATURE BIOTECHNOLOGY, Vol. 15, 1997, Yang, X, et al., "Homologous recombination based modification in *Escherichia coli* and germline transmission in transgenic mice of a bacterial artificial chromosome," pp. 859-865.
- \_\_\_\_ PROC. NATL. ACAD. SCI. USA, Vol. 97, 2000, Yu, D., et al., "An efficient recombination system for chromosome engineering in *Escherichia coli*," pp. 5978-5983.
- \_\_\_\_ CURR OPIN BIOTECHNOL, Vol. 9, 1998, Lie, Y.S., and Petropoulos, C.J., "Advances in quantitative PCR technology: 5' nuclease assays," pp. 43-48.
- \_\_\_\_ EUR J CHEM, Vol. 6, 2000, Tan, W., et al., "Molecular Beacons: A Novel DNA Probe for Nucleic Acid and Protein," pp. 1107-1111.
- \_\_\_\_ HUM GENET, Vol. 96, 1995, Laan, M., et al., "Solid-phase minisequencing confirmed by FISH analysis in determination of gene copy number," pp. 275-280.
- \_\_\_\_ TRENDS IN GENETICS, Vol. 13, 1997, Forozan, F., et al., "Genome screening by comparative genomic hybridization," pp. 405-409.

- \_\_\_\_\_ JOURNAL OF CELLULAR BIOCHEMISTRY, Vol. 17G, 1993,  
Thompson, C.T., and Gray, J.W., "Cytogenetic Profiling Using  
Fluorescence *In Situ* Hybridization (FISH) and Comparative  
Genomic Hybridization (CGH)," pp. 139-143.
- \_\_\_\_\_ AMERICAN JOURNAL OF PATHOLOGY, Vol. 145, 1994,  
Houldsworth, J, and Chaganti, R.S.K., "Comparative  
Genomic Hybridization: An Overview," p. 1253-1260.
- \_\_\_\_\_ NATURE GENETICS, Vol. 19, 1998, Lizardi, P.M., et al.,  
"Mutation detection and single-molecule counting using  
isothermal rolling-circle amplification," pp. 225-232.
- \_\_\_\_\_ NUCLEIC ACIDS RESEARCH, Vol. 27, 1999, Mitra, R.D., and  
Church, G.M., "In situ localized amplification and contact  
replication of many individual DNA molecules," pp. e34.
- \_\_\_\_\_ PROC NATL ACAD SCI USA, Vol. 97, 2000, Tomizuka, K., et  
al., "Double trans-chromosomal mice: Maintenance of two  
individual human chromosome fragments containing Ig  
heavy and  $\kappa$  loci and expression of fully human antibodies,"  
pp. 722-727.
- \_\_\_\_\_ NATURE GENETICS, Vol. 20, 1998, Herault, Y., et al.,  
"Engineering chromosomes in mice through targeted meiotic  
recombination (TAMERE)," pp. 381-384.


REG 780BZ  
USSN Not Yet Known  
File Date: Filed Herewith  
Murphy, et al.  
Information Disclosure Statement

EXAMINER  
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:   
Linda O. Palladino  
Reg. No. 45,636  
Patent Agent for Applicant  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400